Fri, November 10, 2023

Chris Shibutani Maintained (AMLX) at Strong Buy with Decreased Target to $40 on, Nov 10th, 2023

Chris Shibutani of Goldman Sachs, Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy with Decreased Target from $46 to $40 on, Nov 10th, 2023.

Chris, nor any peers, have made any analyst calls on AMLX in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30